20-Feb-2026
VolitionRx Issues Shares to Satisfy Convertible Note Obligations
TipRanks (Fri, 20-Feb 5:47 PM ET)
Volition Announces the Appointment of New Distributor for Nu.Q Discover
PRNewswire (Tue, 10-Feb 8:07 AM ET)
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
PRNewswire (Mon, 9-Feb 5:20 PM ET)
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
PRNewswire (Wed, 4-Feb 8:45 AM ET)
VNRX Moves Toward French Reimbursement Milestone as Nu.Q® Cancer Assays Gain Institutional Backing
Market Chameleon (Fri, 30-Jan 6:45 AM ET)
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q Cancer Assays
PRNewswire (Fri, 30-Jan 8:50 AM ET)
Volition Announces Data to Support Use of Nu.Q NETs in New Indication
PRNewswire (Tue, 27-Jan 8:00 AM ET)
Market Chameleon (Tue, 20-Jan 6:07 AM ET)
Volition Continues to Extend Access to Nu.Q Vet Cancer Test
PRNewswire (Tue, 20-Jan 8:25 AM ET)
Volition Sponsors Symposium at Veterinary Meeting and Expo
PRNewswire (Fri, 16-Jan 8:45 AM ET)
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Volitionrx trades on the AMEX stock market under the symbol VNRX.
As of February 20, 2026, VNRX stock price declined to $0.20 with 1,118,228 million shares trading.
VNRX has a beta of 0.17, meaning it tends to be less sensitive to market movements. VNRX has a correlation of 0.00 to the broad based SPY ETF.
VNRX has a market cap of $26.77 million. This is considered a Sub-Micro Cap stock.
Last quarter Volitionrx reported $627,277 in Revenue and -$.05 earnings per share. This fell short of revenue expectation by $-1 million and met earnings estimates .
In the last 3 years, VNRX traded as high as $2.10 and as low as $.18.
The top ETF exchange traded funds that VNRX belongs to (by Net Assets): VXF.
VNRX has underperformed the market in the last year with a price return of -65.7% while the SPY ETF gained +14.1%. VNRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -40.8% and -19.7%, respectively, while the SPY returned +6.0% and -0.2%, respectively.
VNRX support price is $.19 and resistance is $.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VNRX shares will trade within this expected range on the day.